Voyager Therapeutics (NASDAQ:VYGR) Given “Outperform” Rating at Wedbush

Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “outperform” rating reiterated by stock analysts at Wedbush in a research report issued to clients and investors on Tuesday,RTT News reports. They currently have a $9.00 target price on the stock, down from their prior target price of $11.00. Wedbush’s price target would suggest a potential upside of 114.29% from the stock’s current price.

A number of other analysts have also recently commented on the stock. Citigroup started coverage on shares of Voyager Therapeutics in a research note on Monday, December 2nd. They issued a “buy” rating and a $12.00 price target for the company. Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a report on Thursday, November 14th. StockNews.com lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Cantor Fitzgerald started coverage on Voyager Therapeutics in a research note on Friday, January 10th. They set an “overweight” rating and a $5.73 target price for the company. Finally, Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $15.72.

Voyager Therapeutics Trading Down 21.1 %

Shares of NASDAQ VYGR traded down $1.12 during mid-day trading on Tuesday, hitting $4.20. The company had a trading volume of 1,381,874 shares, compared to its average volume of 368,334. The firm has a 50-day simple moving average of $5.74 and a two-hundred day simple moving average of $6.37. The company has a market capitalization of $229.45 million, a PE ratio of 5.92 and a beta of 0.91. Voyager Therapeutics has a one year low of $4.13 and a one year high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The firm had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. During the same period last year, the company earned ($0.59) earnings per share. Sell-side analysts expect that Voyager Therapeutics will post -0.91 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the sale, the chief operating officer now directly owns 112,328 shares in the company, valued at approximately $634,653.20. This represents a 5.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders sold 10,778 shares of company stock valued at $58,548. 4.53% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of VYGR. Hunter Perkins Capital Management LLC increased its holdings in shares of Voyager Therapeutics by 3.3% during the third quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock worth $375,000 after buying an additional 2,025 shares in the last quarter. Empowered Funds LLC grew its position in Voyager Therapeutics by 5.4% during the 3rd quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock worth $262,000 after acquiring an additional 2,278 shares during the last quarter. Rhumbline Advisers increased its holdings in Voyager Therapeutics by 3.4% in the 4th quarter. Rhumbline Advisers now owns 71,497 shares of the company’s stock worth $405,000 after purchasing an additional 2,354 shares in the last quarter. Picton Mahoney Asset Management raised its position in Voyager Therapeutics by 71.1% in the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock valued at $33,000 after purchasing an additional 2,444 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Voyager Therapeutics by 2.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 137,477 shares of the company’s stock valued at $804,000 after purchasing an additional 3,473 shares in the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.